In previous studies performed by us, we were able to demonstrate that modulation of the first line immune response, including microglia and macrophages, by administration of interleukin-13, leads to protection of myelin in a mouse model for MS. In a next step, we want to study this effect in a human context. For this, we will mimic the environment of an MS brain in the laboratory by using human stem cells. Starting from these stem cells, we will derive oligodendrocytes, neurons, microglia and macrophages. By combining oligodendrocytes with neurons, these will start producing myelin sheath. Next, the breakdown of myelin will be induced by the addition of specific toxins. Finally, microglia and macrophages will be added, with or without interleukin-13, to study the effect on myelin breakdown.
The development of a human iPSC-derived in vitro demyelination model for studying the effect of IL13-induced M2-activated macrophages and microglia on myelin preservation and/or remyelination.